Zmienności genetyczne w genach receptorów chemokin zapalnych mózgu u pacjentów z epilepsją: badanie wstępne
Genetic Variations in Neuroinflammatory Chemokine Receptor Genes in Patients with Epilepsy: An Exploratory Study
W skrócie
Badacze sprawdzili, czy zmienności genetyczne w genach odpowiedzialnych za białka prozapalne w mózgu mogą wpływać na to, jak dobrze leki przeciwpadaczkowe działają u pacjentów z epilepsją. U 22 pacjentów leczonych lekami przeciwpadaczkowymi znaleźli siedem zmienności genetycznych, ale nie wykazały one związku z tym, czy pacjenci dobrze reagowali na leczenie. Autorzy podkreślają, że badanie było wstępne i na zbyt małej grupie, by wyciągać ostateczne wnioski, i że potrzebne są większe badania.
Oryginalny abstract (angielski)
Epilepsy is a common neurological disorder in which genetic and neuroinflammatory mechanisms may contribute to differences in seizure control. Chemokine receptor signaling plays an important role in inflammatory processes, and genetic variations in neuroinflammatory chemokine receptor genes may potentially influence the prognosis of epilepsy. This study aimed to investigate genetic variations in the neuroinflammatory chemokine receptor genes and in patients with epilepsy and to explore their potential association with seizure control during treatment. Targeted next-generation sequencing (tNGS) was performed to investigate genetic variations in the and genes using genomic DNA obtained from 22 patients with epilepsy receiving antiseizure medication (ASM) treatment with levetiracetam and/or valproic acid. Patients were classified into two groups according to seizure frequency to evaluate the association between genetic variation and clinical prognosis. A total of seven genetic variants were identified in the and genes, including three variants in and four variants in . However, sufficient genotype variation for group-wise comparisons was available only for CCR5 rs1799988 and rs1800023. No significant differences were observed in the genotype or allele distributions of the and gene variants between the responsive and persistent groups. The two variants, rs1799988 and rs1800023, showed strong linkage disequilibrium (D' = 1.000, r = 0.913) and were included in a single haplotype block. None of the identified haplotypes was significantly associated with seizure control. In this preliminary cohort, no statistically significant associations were detected between the analyzed genetic variations and seizure control during treatment; however, the limited sample size may have reduced the statistical power to detect potential associations. Strong linkage disequilibrium was observed between rs1799988 and rs1800023 (D' = 1.000, r = 0.913), consistent with previously reported patterns. Given the small sample size and the limited number of informative variants, these findings should be interpreted as preliminary and hypothesis-generating rather than as evidence for or against a genetic contribution to seizure control. Larger, independent cohorts are needed to assess the potential clinical relevance of and variation in epilepsy.